Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®
PHASE1CompletedINTERVENTIONAL
Enrollment
350
Participants
Timeline
Start Date
March 31, 2002
Study Completion Date
March 31, 2003
Conditions
Smallpox
Interventions
BIOLOGICAL
Cell-Cultured Smallpox Vaccine compared to Dryvax®
Trial Locations (1)
40536-0084
University of Kentucky Medical Center, Lexington
All Listed Sponsors
lead
DynPort Vaccine Company LLC, A GDIT Company
INDUSTRY
NCT00042094 - Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax® | Biotech Hunter | Biotech Hunter